Zepp Health Corporation SEC Filings

Zepp Health Corporation was the subject of a Schedule 13G reporting passive beneficial ownership by Millennium-affiliated entities and Integrated Core Strategies.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each reported beneficial ownership of 6,634,592 Class A Ordinary Shares, representing 5.8% of the class, with shared voting and dispositive power and 0 sole power. Integrated Core Strategies (US) LLC reported beneficial ownership of 6,285,648 shares, or 5.5%, also with shared voting and dispositive power and none sole.

The certification states the securities were not acquired and are not held for the purpose of changing or influencing control. The CUSIP (98945L204) applies to the issuer’s American Depositary Shares, and each ADS represents 16 Class A Ordinary Shares.

Allspring Global Investments Holdings, LLC filed an amendment to a Schedule 13G reporting beneficial ownership of 3,324,544 ADRs of Zepp Health Corp (symbol ZEPP), representing 2.9% of the class. The filing states these shares are held in the ordinary course of business with sole voting and sole dispositive power over all reported shares, and were not acquired to influence control of the issuer. The record lists client accounts of investment advisers affiliated with Allspring as the owners of record and confirms no client is known to hold more than 5% individually. The filing is signed by a Senior Compliance Manager and cites related subsidiaries in Exhibit A.

Form 144 notice for Zepp Health Corp (ZEPP) reports a proposed sale of 3,000 American Depositary Receipts (ADRs) by a person who acquired them as founder shares on 02/08/2018 from the issuer. The filer plans to sell the ADRs through Piper Sandler & Co. on the NYSE, with an aggregate market value listed at $133,590 and an approximate sale date of 09/29/2025.

The filing states there were no other securities sold by the seller in the past three months and includes the seller's representation that they are not aware of any undisclosed material adverse information about the issuer. The number of ADRs outstanding is reported as 14,591,331, providing context for the size of the proposed sale relative to total shares.

Zepp Health Corporation filed a Form 144/A notifying a proposed sale of 11,000 American Depositary Receipts (ADRs) representing its common stock, with an aggregate market value of $411,070 and approximately 7,173,522 shares outstanding. The proposed approximate date of sale is 09/04/2025 on the NYSE. The ADRs to be sold were acquired on 02/12/2018 through vesting of a restricted stock award from Zepp Health Corporation; the original grant comprised 25,000 shares and payment was recorded as vesting of a restricted share award on the same date. The filer reports no securities sold in the past three months and includes the standard representation that the seller does not possess undisclosed material adverse information.

Zepp Health Corporation Form 144 reports a proposed sale of 44,000 Class A ordinary shares (American depositary shares representing underlying Class A shares) with an aggregate market value of $411,070.00. The shares represent a small portion of the company's outstanding stock of 114,776,364 shares and are planned to be sold on the NYSE with an approximate sale date of 09/04/2025. The filer acquired the securities on 02/12/2018 through stock options that vested on that date. The filing states there were no securities sold in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.

Zepp Health Corporation (ZEPP) filing a Form 144 notifies a proposed sale of 1,745 ADRs representing American depositary shares, with an aggregate market value of $60,656.20. The ADRs trade on the NYSE and the filing lists an approximate sale date of 08/27/2025. The securities were acquired through the vesting of restricted share units from Zepp Health between March 2018 and February 2020, and no sales by the holder in the past three months were reported.

Amendment No. 7 to Schedule 13G discloses that FIL Limited, Pandanus Partners, L.P. and Pandanus Associates, Inc. have completely exited their position in Zepp Health Corp (symbol ZEPP). As of the event date 31 Jul 2025, the group reports 0 Class A common shares (CUSIP CIB882000), equating to 0.0 % of the outstanding class. Consequently, the filers now fall below the 5 % reporting threshold. All voting and dispositive powers are reported as 0, and the certification confirms the securities were held in the ordinary course, not to influence control. The filing is signed 06 Aug 2025 by Richard Bourgelas under powers of attorney for each entity.